BTIG Research Reaffirms Neutral Rating for Aardvark Therapeutics (NASDAQ:AARD)

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “neutral” rating reiterated by research analysts at BTIG Research in a research report issued to clients and investors on Monday, Benzinga reports.

A number of other brokerages also recently weighed in on AARD. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th. Royal Bank Of Canada restated a “sector perform” rating and set a $6.00 price objective on shares of Aardvark Therapeutics in a research note on Thursday, September 24th. Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $13.12.

Aardvark Therapeutics Stock Performance

NASDAQ:AARD opened at $4.04 on Monday. The company has a market capitalization of $88.40 million, a price-to-earnings ratio of -1.26 and a beta of 3.80. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $16.60. The stock has a 50-day simple moving average of $5.82 and a 200 day simple moving average of $5.29.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.21. On average, equities research analysts forecast that Aardvark Therapeutics will post -3.17 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $5.18, for a total value of $321,160.00. Following the transaction, the insider owned 35,475 shares of the company’s stock, valued at $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 17.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aardvark Therapeutics

Several institutional investors have recently made changes to their positions in AARD. Bank of New York Mellon Corp grew its stake in shares of Aardvark Therapeutics by 30.8% in the first quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock worth $111,000 after purchasing an additional 6,905 shares in the last quarter. Susquehanna International Group LLP acquired a new position in shares of Aardvark Therapeutics during the second quarter valued at $138,000. Ieq Capital LLC acquired a new position in shares of Aardvark Therapeutics during the second quarter valued at $221,000. J. Goldman & Co LP bought a new stake in shares of Aardvark Therapeutics during the second quarter valued at about $233,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Aardvark Therapeutics during the first quarter valued at about $267,000.

More Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Neutral Sentiment: BTIG Research reaffirmed its “neutral” rating on Aardvark, suggesting limited near-term conviction while the company’s clinical and legal issues develop. Aardvark Therapeutics’ Neutral Rating Reaffirmed at BTIG Research
• Negative Sentiment: Pomerantz announced that a class action has been filed in federal court against Aardvark and certain officers and directors. The case covers investors who bought shares in or traceable to the February 2025 IPO, or acquired Aardvark securities from February 13, 2025, through May 14, 2026, under alleged violations of federal securities laws. Pomerantz Class Action Announcement
• Negative Sentiment: The complaints allege that Aardvark’s disclosures described its ARD-101 therapy as largely restricted to the gut and without serious adverse events, but failed to adequately disclose specific cardiac safety concerns that later resulted in a full FDA clinical hold. These allegations have not been proven in court, but they increase regulatory, litigation and potential financial risks for shareholders. SueWallSt Aardvark Lawsuit Notice
• Negative Sentiment: Several investor-rights firms repeated the October 13 lead-plaintiff deadline, increasing visibility around the lawsuit and reinforcing concerns about possible shareholder losses, defense costs and reputational damage. The announcements themselves do not represent additional company operating results. Faruqi Securities Class Action Deadline Notice

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.